NR1H3 and cancer: Moreover, toavoid potential toxic effects due to LXRα-induced liponeogenesis,recent agonists were rather designed to preferentially induce LXRßinstead of LXRα.16−18 Therefore, the currently available LXR agonists donot allow for specific activation of LXRα, making them unsuitablefor lipotoxic cancer therapy.